AMIX Overview

Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.

Wall Street analysts forecast AMIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMIX is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Autonomix Medical Inc revenue for the last quarter amounts to -3.34M USD, increased 21.70

Autonomix Medical Inc. EPS for the last quarter amounts to -2976000.00 USD, increased 29.05

Autonomix Medical Inc (AMIX) has 8 emplpoyees as of March 26 2026.

Today AMIX has the market capitalization of 4.94M USD.